New data and partnerships are advancing brain-penetrant enzyme therapy, targeted antibodies, flexible obesity dosing, and frontline lymphoma treatment strategies.
|Articles|February 12, 2008
CEO of Genelabs Resigns
Author(s)BioPharm International Editors
James A.D. Smith, president, chief executive officer, and director of Genelabs Technologies, Inc. (Redwood City, CA) has resigned.
Advertisement
James A.D. Smith, president, chief executive officer, and director of Genelabs Technologies, Inc. (Redwood City, CA) has resigned. Until a successor is appointed, Irene A. Chow, executive chair of Genelabs’ board of directors, and Frederick W. Driscoll, CFO, will assume leadership responsibilities.
Advertisement
Related to this article
Topline phase 3 data show epcoritamab plus R-CHOP reduced the risk of progression or death by 51% in newly diagnosed diffuse large B-cell lymphoma.
Part 2 of the VK2735 maintenance study tests whether daily or weekly oral tablets can hold weight loss first achieved with weekly subcutaneous injections.
CSL and Alentis will co-develop lixudebart, an antibody targeting claudin-1, across 3 rare kidney and liver disease indications.
AL050 aims to treat GBA1-driven Parkinson disease by delivering a GCase enzyme across the blood-brain barrier.
Survodutide advances metabolic disease treatment, while biosimilar capacity expands, FDA delays hemophilia review, and lupus data support next steps.
Litifilimab extended skin responses through 52 weeks in phase 2 AMETHYST data in cutaneous lupus erythematosus, with phase 3 results expected in 2027.
Manufacturing remediation, not efficacy or safety data, is delaying US approval of Novo's h+emophilia A therapy denecimig.
Advertisement
Advertisement